Evidence map›Paper›PMID 40097795›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2025

Ceftazidime-avibactam use in hematology patients: single-center experience.

Aysun Halacoglu, Mustafa Koroglu, Mehmet Ozen

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Letter to the editor: "Ceftazidime-avibactam use in hematology patients: single-center experience".European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025
    Article
  3. JAC-antimicrobial resistance · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Aysun HalacogluSchool of Medicine, Department of Hematology and Bone Marrow Transplantation Unit, Istinye University, Medicalpark Gaziosmanpasa Hospital, Istanbul, Turkey. aysunhalacoglu@hotmail.com.
Mustafa KorogluSchool of Medicine, Department of Hematology and Bone Marrow Transplantation Unit, Istinye University, Medicalpark Gaziosmanpasa Hospital, Istanbul, Turkey.
Mehmet OzenSchool of Medicine, Department of Hematology and Bone Marrow Transplantation Unit, Istinye University, Medicalpark Gaziosmanpasa Hospital, Istanbul, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the efficacy of the cephalosporin/ beta lactamase inhibitor combination ceftazidime-avibactam in hematology patients with hematopoietic stem cell transplantation or receiving chemotherapy alone. MATERIALS AND

methodsIn this study, 80 patients who were followed up in the Stem Cell Transplant Center and Hematology Clinic of Istinye University Gaziosmanpaşa Medicalpark Hospital between June 2022 and May 2024 and who received ceftazidime-avibactam treatment for at least 3 days during their hospitalization were evaluated. Demographic characteristics, infectious processes, duration of hospitalization before culture, neutrophil levels and neutropenia duration at the time of treatment initiation, previous antibiotic exposure, Charlson's Comorbidity index, mechanical ventilation needs and mortality rates were recorded retrospectively.

resultsOf the patients, 25 (31.25%) were female and 55 (68.75%) were male. The mean age was 50 years (18-86). Thirty-four (42.5%) patients received allogeneic hematopoietic stem cell transplantation and 17 (21.25%) patients received autologous hematopoietic stem cell transplantation. Only 29 (36.25%) patients received chemotherapy. When ceftazidime-avibactam treatment was initiated, 42 (52.5%) patients had a neutrophil count < 0.1 × 10

conclusionMortality due to resistant microorganisms is high in hematologic patients during stem cell transplantation and non-transplant period. Age, pneumonia and need for mechanical ventilation and duration of neutropenia are the most important mortality indicators in hematologic patients. Ceftazidime-avibactam is an effective treatment option in appropriate patients and the clinical response will be better if it can be started before the need for mechanical ventilation develops.

Indexed as

Anti-Bacterial AgentsAzabicyclo Compoundsbeta-Lactamase InhibitorsCeftazidimeAdolescentAdultAgedAged, 80 and overDrug CombinationsFemaleHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo Compoundsbeta-Lactamase InhibitorsCeftazidimeDrug CombinationsCeftazidime-avibactamHematopoieticStem cell

Identifiers

PMID40097795

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.